Please find all related articles below.
EPHA believes that greater transparency is vital to ensure proper democratic and public debate about the impact of trade policy on population health, following Greenpeace Netherlands’ release of classified TTIP negotiating documents
By Zoltán Massay-Kosubek, @EU_ZMK, Policy Coordinator for Healthy Trade and Health Equity, EPHA
EPHA believes that greater transparency is vital to ensure proper democratic and public debate about the impact of trade policy on population health, (...)
In February, trade negotiators from the EU and the US met in Brussels for the twelfth round of negotiations on the Transatlantic Trade and Investment Partnership (TTIP) - behind closed doors. Amongst other things, they discussed an EU proposal on regulatory cooperation on Generic Medicines. The negotations could have dramatic impacts on affordability and accessibility of medicines in Europe, depending on whether the negotiators prioritise public health goals. Is the negotiators’ main (...)
On 15 July 2015 EPHA and Wemos hosted an event in the Members’ Salon at the European Parliament to highlight the issue of added therapeutic value (ATV) in medicines.
Several studies carried out at EU member state level indicate that the majority of medicines authorised for use have little-to-no ATV in comparison with existing treatments. This means that public money is being spent on new, costly medicines which have limited ATV, whilst also using up resources which might otherwise be (...)
Supplying poor and developing countries with medicines at sustainable, reduced prices is one of the most important tools in the fight against major diseases, especially the “Big Three”, namely HIV, TB and malaria. After more than a decade since the Council Regulation (EC) 953/2003 came into force, to avoid trade diversion into the European Union of certain key medicines, stakeholders came together to discuss the overall impact of the Regulation at a workshop on 15 July 2015, (...)